FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383301668> ?p ?o ?g. }

• W4383301668 endingPage "e2321971" @default.
• W4383301668 startingPage "e2321971" @default.
• W4383301668 abstract "Importance Anticoagulation management services (AMSs; ie, warfarin clinics) have evolved to include patients treated with direct oral anticoagulants (DOACs), but it is unknown whether DOAC therapy management services improve outcomes for patients with atrial fibrillation (AF). Objective To compare outcomes associated with 3 DOAC care models for preventing adverse anticoagulation-related outcomes among patients with AF. Design, Setting, and Participants This retrospective cohort study included 44 746 adult patients with a diagnosis of AF who initiated oral anticoagulation (DOAC or warfarin) between August 1, 2016, and December 31, 2019, in 3 Kaiser Permanente (KP) regions. Statistical analysis was conducted from August 2021 through May 2023. Exposures Each KP region used an AMS to manage warfarin but used distinct approaches to DOAC care: (1) usual care (UC) by the prescribing clinician, (2) UC plus an automated population management tool (PMT), or (3) pharmacist-managed AMS care. Propensity scores and inverse probability of treatment weights (IPTWs) were estimated. Direct oral anticoagulant care models were first indirectly compared using warfarin as a common comparator within each region and then directly compared across regions. Main Outcomes and Measures Patients were followed up until the first occurrence of an outcome (composite of thromboembolic stroke, intracranial hemorrhage, other major bleeding, or death), discontinuation of KP membership, or December 31, 2020. Results Overall, 44 746 patients were included: 6182 in the UC care model (3297 DOAC; 2885 warfarin), 33 625 in the UC plus PMT care model (21 891 DOAC; 11 734 warfarin), and 4939 in the AMS care model (2089 DOAC; 2850 warfarin). Baseline characteristics (mean [SD] age, 73.1 [10.6] years, 56.1% male, 67.2% non-Hispanic White, median CHA 2 DS 2 -VASc [congestive heart failure, hypertension, age ≥75 years, diabetes, stroke, vascular disease, age 65-74 years, female sex] score of 3 [IQR, 2-5]) were well balanced after IPTW. Over a median follow-up of 2 years, patients who received the UC plus PMT or AMS care model did not have significantly better outcomes than those who received UC. The incidence rate of the composite outcome was 5.4% per year for DOAC and 9.1% per year for warfarin for those in the UC group, 6.1% per year for DOAC and 10.5% per year for those in the UC plus PMT group, and 5.1% per year for DOAC and 8.0% per year for those in the AMS group. The IPTW-adjusted hazard ratios (HRs) for the composite outcome comparing DOAC vs warfarin were 0.91 (95% CI, 0.79-1.05) in the UC group, 0.85 (95% CI, 0.79-0.90) in the UC plus PMT group, and 0.84 (95% CI, 0.72-0.99) in the AMS group ( P = .62 for heterogeneity across care models). When directly comparing patients receiving DOAC, the IPTW-adjusted HR was 1.06 (95% CI, 0.85-1.34) for the UC plus PMT group vs the UC group and 0.85 (95% CI, 0.71-1.02) for the AMS group vs the UC group. Conclusions and Relevance This cohort study did not find appreciably better outcomes for patients receiving DOAC who were managed by either a UC plus PMT or AMS care model compared with UC." @default.
• W4383301668 created "2023-07-07" @default.
• W4383301668 creator A5007071274 @default.
• W4383301668 creator A5014865134 @default.
• W4383301668 creator A5022212984 @default.
• W4383301668 creator A5031793125 @default.
• W4383301668 creator A5031963424 @default.
• W4383301668 creator A5040195829 @default.
• W4383301668 creator A5040321180 @default.
• W4383301668 creator A5044669734 @default.
• W4383301668 creator A5078470996 @default.
• W4383301668 creator A5081829680 @default.
• W4383301668 creator A5084849999 @default.
• W4383301668 creator A5087247666 @default.
• W4383301668 creator A5087519827 @default.
• W4383301668 creator A5089313477 @default.
• W4383301668 date "2023-07-06" @default.
• W4383301668 modified "2023-09-25" @default.
• W4383301668 title "Association of Direct Oral Anticoagulation Management Strategies With Clinical Outcomes for Adults With Atrial Fibrillation" @default.
• W4383301668 cites W1508825876 @default.
• W4383301668 cites W1601608895 @default.
• W4383301668 cites W1969388541 @default.
• W4383301668 cites W2016653818 @default.
• W4383301668 cites W2049491523 @default.
• W4383301668 cites W2058611793 @default.
• W4383301668 cites W2067068312 @default.
• W4383301668 cites W2101963942 @default.
• W4383301668 cites W2105814725 @default.
• W4383301668 cites W2122069275 @default.
• W4383301668 cites W2123298478 @default.
• W4383301668 cites W2124601103 @default.
• W4383301668 cites W2154328340 @default.
• W4383301668 cites W2166889936 @default.
• W4383301668 cites W2170223607 @default.
• W4383301668 cites W2173171740 @default.
• W4383301668 cites W2298449147 @default.
• W4383301668 cites W2343917423 @default.
• W4383301668 cites W2566947560 @default.
• W4383301668 cites W2601858066 @default.
• W4383301668 cites W2617341415 @default.
• W4383301668 cites W2781162030 @default.
• W4383301668 cites W2898546427 @default.
• W4383301668 cites W2901676439 @default.
• W4383301668 cites W2903014248 @default.
• W4383301668 cites W3005342950 @default.
• W4383301668 cites W3022423927 @default.
• W4383301668 cites W3033253379 @default.
• W4383301668 cites W3184662840 @default.
• W4383301668 cites W4206007300 @default.
• W4383301668 cites W4307337285 @default.
• W4383301668 doi "https://doi.org/10.1001/jamanetworkopen.2023.21971" @default.
• W4383301668 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37410461" @default.
• W4383301668 hasPublicationYear "2023" @default.
• W4383301668 type Work @default.
• W4383301668 citedByCount "0" @default.
• W4383301668 crossrefType "journal-article" @default.
• W4383301668 hasAuthorship W4383301668A5007071274 @default.
• W4383301668 hasAuthorship W4383301668A5014865134 @default.
• W4383301668 hasAuthorship W4383301668A5022212984 @default.
• W4383301668 hasAuthorship W4383301668A5031793125 @default.
• W4383301668 hasAuthorship W4383301668A5031963424 @default.
• W4383301668 hasAuthorship W4383301668A5040195829 @default.
• W4383301668 hasAuthorship W4383301668A5040321180 @default.
• W4383301668 hasAuthorship W4383301668A5044669734 @default.
• W4383301668 hasAuthorship W4383301668A5078470996 @default.
• W4383301668 hasAuthorship W4383301668A5081829680 @default.
• W4383301668 hasAuthorship W4383301668A5084849999 @default.
• W4383301668 hasAuthorship W4383301668A5087247666 @default.
• W4383301668 hasAuthorship W4383301668A5087519827 @default.
• W4383301668 hasAuthorship W4383301668A5089313477 @default.
• W4383301668 hasBestOaLocation W43833016681 @default.
• W4383301668 hasConcept C126322002 @default.
• W4383301668 hasConcept C127413603 @default.
• W4383301668 hasConcept C167135981 @default.
• W4383301668 hasConcept C177713679 @default.
• W4383301668 hasConcept C17923572 @default.
• W4383301668 hasConcept C194828623 @default.
• W4383301668 hasConcept C2776301958 @default.
• W4383301668 hasConcept C2778715236 @default.
• W4383301668 hasConcept C2779161974 @default.
• W4383301668 hasConcept C2780645631 @default.
• W4383301668 hasConcept C2908647359 @default.
• W4383301668 hasConcept C71924100 @default.
• W4383301668 hasConcept C72563966 @default.
• W4383301668 hasConcept C78519656 @default.
• W4383301668 hasConcept C99454951 @default.
• W4383301668 hasConceptScore W4383301668C126322002 @default.
• W4383301668 hasConceptScore W4383301668C127413603 @default.
• W4383301668 hasConceptScore W4383301668C167135981 @default.
• W4383301668 hasConceptScore W4383301668C177713679 @default.
• W4383301668 hasConceptScore W4383301668C17923572 @default.
• W4383301668 hasConceptScore W4383301668C194828623 @default.
• W4383301668 hasConceptScore W4383301668C2776301958 @default.
• W4383301668 hasConceptScore W4383301668C2778715236 @default.
• W4383301668 hasConceptScore W4383301668C2779161974 @default.
• W4383301668 hasConceptScore W4383301668C2780645631 @default.
• W4383301668 hasConceptScore W4383301668C2908647359 @default.
• W4383301668 hasConceptScore W4383301668C71924100 @default.

• next